Difference between revisions of "Etoposide (Vepesid)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Sarcoma" to "[[Category:Soft tissue sarcoma") |
m |
||
| Line 22: | Line 22: | ||
*[[Hemophagocytic lymphohistiocytosis]] | *[[Hemophagocytic lymphohistiocytosis]] | ||
*[[Hepatobiliary cancer]] | *[[Hepatobiliary cancer]] | ||
| − | |||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
| + | *[[Langerhans cell histiocytosis]] | ||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
*[[Mediastinal gray-zone lymphoma]] | *[[Mediastinal gray-zone lymphoma]] | ||
| Line 52: | Line 52: | ||
*11/10/1983: Initial FDA approval for refractory [[Testicular cancer | testicular tumors]] | *11/10/1983: Initial FDA approval for refractory [[Testicular cancer | testicular tumors]] | ||
==Also known as== | ==Also known as== | ||
| + | *'''Code names:''' VP-16, VP-TEC, VP 16213 | ||
| + | *'''Generic name:''' etoposide phosphate | ||
| + | *'''Brand names:''' | ||
{| border="1" style="text-align:center;" | {| border="1" style="text-align:center;" | ||
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms''' | !colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms''' | ||
|- | |- | ||
| − | + | |Aside | |
| − | | Aside | + | |Beposid |
| − | | Beposid | ||
|Bioposide | |Bioposide | ||
| − | |||
| − | |||
|Celltop | |Celltop | ||
|Citodox | |Citodox | ||
| − | |||
|Epocin | |Epocin | ||
|Eposid | |Eposid | ||
|Eposide | |Eposide | ||
| + | |- | ||
|Eposido | |Eposido | ||
|Eposin | |Eposin | ||
| Line 72: | Line 72: | ||
|ETO | |ETO | ||
|Etocris | |Etocris | ||
| − | |||
|Etomedac | |Etomedac | ||
|Etonolver | |Etonolver | ||
|Etopofos | |Etopofos | ||
| + | |- | ||
|Etopophos | |Etopophos | ||
|Etopos | |Etopos | ||
|Etoposid | |Etoposid | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|Etoposido | |Etoposido | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|Etopoxan | |Etopoxan | ||
|Etopul | |Etopul | ||
| Line 114: | Line 90: | ||
|Fytop | |Fytop | ||
|Fytosid | |Fytosid | ||
| − | |||
|Labimion | |Labimion | ||
|Lastet | |Lastet | ||
| + | |Lastet S | ||
|- | |- | ||
| − | |||
|Neoplaxol | |Neoplaxol | ||
|Nexvep | |Nexvep | ||
|Onkoposid | |Onkoposid | ||
|Optasid | |Optasid | ||
| − | |||
|Percas | |Percas | ||
|Posid | |Posid | ||
| − | |||
|Posidon | |Posidon | ||
|Posyd | |Posyd | ||
| + | |- | ||
|Riboposid | |Riboposid | ||
|Sintopozid | |Sintopozid | ||
| Line 135: | Line 109: | ||
|Toposin | |Toposin | ||
|Topresid | |Topresid | ||
| − | |||
|Tosuben | |Tosuben | ||
|Vepefos | |Vepefos | ||
| + | |- | ||
|Vepeside | |Vepeside | ||
| − | |||
| − | |||
| − | |||
|Vepsid | |Vepsid | ||
|Vepside | |Vepside | ||
|- | |- | ||
| − | |||
| − | |||
| − | |||
|} | |} | ||
| Line 154: | Line 122: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| Line 176: | Line 143: | ||
[[Category:Hemophagocytic lymphohistiocytosis medications]] | [[Category:Hemophagocytic lymphohistiocytosis medications]] | ||
[[Category:Hepatobiliary cancer medications]] | [[Category:Hepatobiliary cancer medications]] | ||
| − | |||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | [[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | ||
| + | [[Category:Langerhans cell histiocytosis medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Mediastinal gray-zone lymphoma medications]] | [[Category:Mediastinal gray-zone lymphoma medications]] | ||
Revision as of 20:09, 6 November 2017
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Adult T-cell leukemia-lymphoma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Ewing's sarcoma
- Extranodal NK/T-cell lymphoma, nasal type
- Follicular lymphoma
- Hemophagocytic lymphohistiocytosis
- Hepatobiliary cancer
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Langerhans cell histiocytosis
- Mantle cell lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- NK/T-cell lymphoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Soft tissue sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Unknown primary
Patient drug information
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/10/1983: Initial FDA approval for refractory testicular tumors
Also known as
- Code names: VP-16, VP-TEC, VP 16213
- Generic name: etoposide phosphate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Aside | Beposid | Bioposide | Celltop | Citodox | Epocin | Eposid | Eposide |
| Eposido | Eposin | Epsidox | ETO | Etocris | Etomedac | Etonolver | Etopofos |
| Etopophos | Etopos | Etoposid | Etoposido | Etopoxan | Etopul | Etosid | Etosin |
| Eunades CS | Euvaxon | Exitop | Fytop | Fytosid | Labimion | Lastet | Lastet S |
| Neoplaxol | Nexvep | Onkoposid | Optasid | Percas | Posid | Posidon | Posyd |
| Riboposid | Sintopozid | Toposar | Toposide | Toposin | Topresid | Tosuben | Vepefos |
| Vepeside | Vepsid | Vepside | |||||
References
Categories:
- Drug index
- Intravenous medications
- Oral medications
- Irritant chemotherapy
- Topoisomerase inhibitors
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Cancer of unknown primary medications
- Central nervous system (CNS) cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Ewing's sarcoma medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Hemophagocytic lymphohistiocytosis medications
- Hepatobiliary cancer medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Langerhans cell histiocytosis medications
- Mantle cell lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- NK/T-cell lymphoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Transplant medications
- Drugs FDA approved in 1983
- WHO Essential Cancer Medicine